Amicus Therapeutics, Inc. $FOLD Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lessened its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,642,157 shares of the biopharmaceutical company’s stock after selling 136,494 shares during the period. William Blair Investment Management LLC’s holdings in Amicus Therapeutics were worth $83,900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Allianz Asset Management GmbH boosted its stake in Amicus Therapeutics by 4.4% in the second quarter. Allianz Asset Management GmbH now owns 387,776 shares of the biopharmaceutical company’s stock valued at $2,222,000 after acquiring an additional 16,367 shares in the last quarter. CWM LLC boosted its stake in Amicus Therapeutics by 395.9% in the second quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 7,502 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Amicus Therapeutics by 63.3% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 17,887 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 6,932 shares during the last quarter. Inspire Investing LLC boosted its stake in shares of Amicus Therapeutics by 59.6% during the second quarter. Inspire Investing LLC now owns 68,250 shares of the biopharmaceutical company’s stock worth $391,000 after buying an additional 25,479 shares during the period. Finally, KLP Kapitalforvaltning AS boosted its stake in shares of Amicus Therapeutics by 17.5% during the second quarter. KLP Kapitalforvaltning AS now owns 49,600 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 7,400 shares during the period.

Amicus Therapeutics Trading Down 0.9%

NASDAQ FOLD opened at $8.04 on Friday. The stock has a market capitalization of $2.48 billion, a P/E ratio of -66.99 and a beta of 0.56. Amicus Therapeutics, Inc. has a 52-week low of $5.51 and a 52-week high of $12.65. The firm has a 50-day moving average price of $7.88 and a 200 day moving average price of $6.89. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Morgan Stanley upgraded shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research note on Thursday, July 17th. Wall Street Zen downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 8th. Finally, Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.88.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.